### KDM4E Gene Overview

**Gene Symbol**: KDM4E  
**Function**: KDM4E encodes a member of the histone lysine demethylase family, specifically responsible for the demethylation of trimethylated Lys9 of histone H3 (H3K9me3). This post-translational modification plays a crucial role in regulating gene expression, and thus, KDM4E is integral to the epigenetic control of various biological processes including development, differentiation, and responses to environmental stimuli.

### 1. Associated Genes
While specific gene associations for KDM4E are not extensively documented above, other members of the KDM4 family (KDM4A, KDM4B, KDM4C) share overlapping functions in demethylation and may be involved in common regulatory pathways. Additionally, interaction with genes involved in transcriptional regulation and chromatin remodeling can be inferred, such as:

- **JUN** (Jun proto-oncogene)
- **FOS** (Fos proto-oncogene)
- Other genes involved in histone modification and epigenetic regulation such as **SETDB1**, **EZH2**, and components of the Polycomb group proteins.

### 2. Aging and Age-Related Diseases
Research indicates that alterations in histone demethylation processes may have implications for aging and age-related diseases:

- **Cellular Senescence**: Dysregulation in the activities of histone demethylases, including KDM4E, has been observed, potentially contributing to the accumulation of senescent cells which are key players in aging and age-related tissue degeneration.
- **Cancer**: KDM4E may play a significant role in the progression of various cancers, as aberrant expression levels can lead to the silencing of tumor suppressor genes or activation of oncogenes. Thus, it may be implicated in age-related prevalence of cancers due to the cumulative effects of genetic and epigenetic changes over time.

### 3. Drug Interactions
While specific drugs targeting KDM4E may not be profoundly documented, broad classes of histone demethylase inhibitors are of interest:

- **Small Molecule Inhibitors**: Several compounds have been proposed to inhibit KDM4 family members (including KDM4E) such as:
  - **GSK-J4**: A selective inhibitor of KDM4A, KDM4B, and KDM4C which has shown some actions on KDM4E.
  - **MI-503** and other related compounds that target histone lysine demethylases.
  
In the context of cancer therapy, ongoing research aims to identify selective inhibitors for KDM4E due to its role in tumorigenesis.

### 4. Pathways and Biological Processes
KDM4E is involved in various biological pathways and processes, including but not limited to:

- **Regulation of Gene Expression**: By demethylating tri- and di-methylated H3K9, it influences chromatin structure and gene transcription.
- **Histone Modification**: KDM4E is part of the post-translational modification cycle of histones, regulating transcriptional activation or repression.
- **Cell Cycle Regulation**: It may have roles in cell proliferation and differentiation due to its impact on key regulatory genes.
- **Developmental Processes**: It potentially has a role in embryonic development and stem cell pluripotency.
- **Response to Hypoxia**: It can influence the cellular response to hypoxic conditions by altering gene expression patterns associated with oxygen levels.

In summary, KDM4E is critical in controlling gene expression through its demethylation action on histones, influencing aging, cancer, and numerous biological pathways. Further studies could elucidate its potential as a therapeutical target in age-related diseases and cancer.